Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 74

1.

Peripheral and central effects of γ-secretase inhibition by semagacestat in Alzheimer's disease.

Doody RS, Raman R, Sperling RA, Seimers E, Sethuraman G, Mohs R, Farlow M, Iwatsubo T, Vellas B, Sun X, Ernstrom K, Thomas RG, Aisen PS; Alzheimer’s Disease Cooperative Study.

Alzheimers Res Ther. 2015 Jun 10;7(1):36. doi: 10.1186/s13195-015-0121-6. eCollection 2015.

2.

A phase 3 trial of semagacestat for treatment of Alzheimer's disease.

Doody RS, Raman R, Farlow M, Iwatsubo T, Vellas B, Joffe S, Kieburtz K, He F, Sun X, Thomas RG, Aisen PS; Alzheimer's Disease Cooperative Study Steering Committee, Siemers E, Sethuraman G, Mohs R; Semagacestat Study Group.

N Engl J Med. 2013 Jul 25;369(4):341-50. doi: 10.1056/NEJMoa1210951.

3.

Phase 2 safety trial targeting amyloid beta production with a gamma-secretase inhibitor in Alzheimer disease.

Fleisher AS, Raman R, Siemers ER, Becerra L, Clark CM, Dean RA, Farlow MR, Galvin JE, Peskind ER, Quinn JF, Sherzai A, Sowell BB, Aisen PS, Thal LJ.

Arch Neurol. 2008 Aug;65(8):1031-8. doi: 10.1001/archneur.65.8.1031.

4.

Amyloid-β(1-15/16) as a marker for γ-secretase inhibition in Alzheimer's disease.

Portelius E, Zetterberg H, Dean RA, Marcil A, Bourgeois P, Nutu M, Andreasson U, Siemers E, Mawuenyega KG, Sigurdson WC, May PC, Paul SM, Holtzman DM, Blennow K, Bateman RJ.

J Alzheimers Dis. 2012;31(2):335-41. doi: 10.3233/JAD-2012-120508.

5.

Neuropathological and biochemical assessments of an Alzheimer's disease patient treated with the γ-secretase inhibitor semagacestat.

Roher AE, Maarouf CL, Kokjohn TA, Whiteside CM, Kalback WM, Serrano G, Belden C, Liebsack C, Jacobson SA, Sabbagh MN, Beach TG.

Am J Neurodegener Dis. 2014 Dec 5;3(3):115-33. eCollection 2014.

6.

Safety profile of semagacestat, a gamma-secretase inhibitor: IDENTITY trial findings.

Henley DB, Sundell KL, Sethuraman G, Dowsett SA, May PC.

Curr Med Res Opin. 2014 Oct;30(10):2021-32. doi: 10.1185/03007995.2014.939167. Epub 2014 Jul 14.

PMID:
24983746
7.

Safety and tolerability of the γ-secretase inhibitor avagacestat in a phase 2 study of mild to moderate Alzheimer disease.

Coric V, van Dyck CH, Salloway S, Andreasen N, Brody M, Richter RW, Soininen H, Thein S, Shiovitz T, Pilcher G, Colby S, Rollin L, Dockens R, Pachai C, Portelius E, Andreasson U, Blennow K, Soares H, Albright C, Feldman HH, Berman RM.

Arch Neurol. 2012 Nov;69(11):1430-40.

PMID:
22892585
8.

A single dose of the γ-secretase inhibitor semagacestat alters the cerebrospinal fluid peptidome in humans.

Hölttä M, Dean RA, Siemers E, Mawuenyega KG, Sigurdson W, May PC, Holtzman DM, Portelius E, Zetterberg H, Bateman RJ, Blennow K, Gobom J.

Alzheimers Res Ther. 2016 Mar 7;8(1):11. doi: 10.1186/s13195-016-0178-x.

9.

Changes in Neuropsychiatric Inventory Associated with Semagacestat Treatment of Alzheimer's Disease.

Rosenberg PB, Lanctôt KL, Herrmann N, Mintzer JE, Porsteinsson AP, Sun X, Raman R.

J Alzheimers Dis. 2016 Aug 10;54(1):373-81. doi: 10.3233/JAD-151113.

PMID:
27567808
10.

Advances in the identification of γ-secretase inhibitors for the treatment of Alzheimer's disease.

D'Onofrio G, Panza F, Frisardi V, Solfrizzi V, Imbimbo BP, Paroni G, Cascavilla L, Seripa D, Pilotto A.

Expert Opin Drug Discov. 2012 Jan;7(1):19-37. doi: 10.1517/17460441.2012.645534. Epub 2011 Dec 14. Review.

PMID:
22468891
11.

Safety, efficacy, and biomarker findings of PBT2 in targeting Abeta as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial.

Lannfelt L, Blennow K, Zetterberg H, Batsman S, Ames D, Harrison J, Masters CL, Targum S, Bush AI, Murdoch R, Wilson J, Ritchie CW; PBT2-201-EURO study group.

Lancet Neurol. 2008 Sep;7(9):779-86. doi: 10.1016/S1474-4422(08)70167-4. Epub 2008 Jul 30. Erratum in: Lancet Neurol. 2009 Nov;8(11):981.

PMID:
18672400
12.

Acute effect on the Aβ isoform pattern in CSF in response to γ-secretase modulator and inhibitor treatment in dogs.

Portelius E, Van Broeck B, Andreasson U, Gustavsson MK, Mercken M, Zetterberg H, Borghys H, Blennow K.

J Alzheimers Dis. 2010;21(3):1005-12. doi: 10.3233/JAD-2010-100573.

PMID:
20634579
13.

Dynamics of {beta}-amyloid reductions in brain, cerebrospinal fluid, and plasma of {beta}-amyloid precursor protein transgenic mice treated with a {gamma}-secretase inhibitor.

Barten DM, Guss VL, Corsa JA, Loo A, Hansel SB, Zheng M, Munoz B, Srinivasan K, Wang B, Robertson BJ, Polson CT, Wang J, Roberts SB, Hendrick JP, Anderson JJ, Loy JK, Denton R, Verdoorn TA, Smith DW, Felsenstein KM.

J Pharmacol Exp Ther. 2005 Feb;312(2):635-43. Epub 2004 Sep 27.

PMID:
15452193
14.

A novel Abeta isoform pattern in CSF reflects gamma-secretase inhibition in Alzheimer disease.

Portelius E, Dean RA, Gustavsson MK, Andreasson U, Zetterberg H, Siemers E, Blennow K.

Alzheimers Res Ther. 2010 Mar 29;2(2):7. doi: 10.1186/alzrt30.

15.

BIIB042, a novel γ-secretase modulator, reduces amyloidogenic Aβ isoforms in primates and rodents and plaque pathology in a mouse model of Alzheimer's disease.

Scannevin RH, Chollate S, Brennan MS, Snodgrass-Belt PA, Peng H, Xu L, Jung MY, Bussiere T, Arastu MF, Talreja T, Xin Z, Dunstan RW, Fahrer D, Rohde E, Dunah AW, Wang J, Kumaravel G, Taveras AG, Moore Arnold H, Rhodes KJ.

Neuropharmacology. 2016 Apr;103:57-68. doi: 10.1016/j.neuropharm.2015.12.006. Epub 2015 Dec 12.

PMID:
26690893
16.

Alzheimer's disease.

De-Paula VJ, Radanovic M, Diniz BS, Forlenza OV.

Subcell Biochem. 2012;65:329-52. doi: 10.1007/978-94-007-5416-4_14. Review.

PMID:
23225010
17.

Semagacestat, a gamma-secretase inhibitor for the potential treatment of Alzheimer's disease.

Imbimbo BP, Peretto I.

Curr Opin Investig Drugs. 2009 Jul;10(7):721-30.

PMID:
19579178
18.

Efficacy and safety of tarenflurbil in mild to moderate Alzheimer's disease: a randomised phase II trial.

Wilcock GK, Black SE, Hendrix SB, Zavitz KH, Swabb EA, Laughlin MA; Tarenflurbil Phase II Study investigators.

Lancet Neurol. 2008 Jun;7(6):483-93. doi: 10.1016/S1474-4422(08)70090-5. Epub 2008 Apr 29. Erratum in: Lancet Neurol. 2008 Jul;7(7):575. Lancet Neurol. 2011 Apr;10(4):297.

PMID:
18450517
19.

Begacestat (GSI-953): a novel, selective thiophene sulfonamide inhibitor of amyloid precursor protein gamma-secretase for the treatment of Alzheimer's disease.

Martone RL, Zhou H, Atchison K, Comery T, Xu JZ, Huang X, Gong X, Jin M, Kreft A, Harrison B, Mayer SC, Aschmies S, Gonzales C, Zaleska MM, Riddell DR, Wagner E, Lu P, Sun SC, Sonnenberg-Reines J, Oganesian A, Adkins K, Leach MW, Clarke DW, Huryn D, Abou-Gharbia M, Magolda R, Bard J, Frick G, Raje S, Forlow SB, Balliet C, Burczynski ME, Reinhart PH, Wan HI, Pangalos MN, Jacobsen JS.

J Pharmacol Exp Ther. 2009 Nov;331(2):598-608. doi: 10.1124/jpet.109.152975. Epub 2009 Aug 11.

PMID:
19671883
20.

Therapeutic intervention for Alzheimer's disease with γ-secretase inhibitors: still a viable option?

Imbimbo BP, Panza F, Frisardi V, Solfrizzi V, D'Onofrio G, Logroscino G, Seripa D, Pilotto A.

Expert Opin Investig Drugs. 2011 Mar;20(3):325-41. doi: 10.1517/13543784.2011.550572. Epub 2011 Jan 11. Review.

PMID:
21222550

Supplemental Content

Support Center